University of Dundee, MSc Human Clinical Embryology and Assisted Conception - Apply now for September 2018
Page URL: https://www.bionews.org.uk/page_90814

First pluripotent stem cell patent granted in Japan

22 September 2008
Appeared in BioNews 476

The Japanese Patent Office has granted the first patent for induced pluripotent stem cells (iPS cells) to Kyoto University, where researcher Shinya Yamanaka produced both the first non-human iPS cells in 2006 and, using the same process, the first human iPS cells in 2007.The Japanese patent, a limited version of a much broader international patent application covering all forms of iPS cell (excluding germ cells) across all species, covers only human iPS cells created using Yamanaka's process based on reprogramming adult cells using four gene factors.

The granting of the patent in Japan was fast-tracked by Patent Office officials so as to make clear the University's claim while the broader patent goes through lengthy processing across the world's other major patent institutions. The urgency in part reflects the contemporaneous progress of a US team headed by James Thomson at the University of Wisconsin which published its own successes in producing human iPS cells on the same day as Yamanaka in 2007.

The international patent applications, some of which are in Yamanaka's name solely (including the potentially lucrative US patent), may eventually cover a huge range of therapeutic applications and future avenues of research. Uncertainties have been raised, however, about whether the patent phrasing does enough to preclude others (such as Thomson's group who used a different set of genetic factors to create their iPS cells) from pursuing patents for their own distinct methods of preparation.

Hideya Hayashi of Kyoto University's iPS Cell Research and Application office is quoted in the journal Nature saying that the aim of the patent is not to restrict others from pursuing iPS technologies but instead to ensure that Yamanaka's group are not tied by other future patent applications. 'We want to remove any potential obstacles to the quick clinical application of IPS technology', Hayashi told Nature, adding that 'we are not trying to confine its use'.

The university has claimed it plans to grant licences and assistance in replicating Yamanaka's technology to institutions and non-profit organisations across Japan. The main concern, preventing a large pharmaceutical company from taking out a patent and then forcing universities to pay for the right to employ the technology, has been partially allayed by this first patent, which secures Yamanaka's basic process until 6 December 2026. However, it will be an anxious wait over the coming year while the rest of the international patents finish being scrutinised.

SOURCES & REFERENCES
Japan fast-tracks stem-cell patent
Nature |  17 September 2008
Japan university gets patent for stem cell breakthrough
AFP |  12 September 2008
Kyoto University obtains patent on iPS stem cells
The Mainichi Daily News |  13 September 2008
Patent on Kyoto U. special iPS stem cell technology approved
Daily Yomiuri |  14 September 2008
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
15 October 2012 - by Dr Dusko Ilic 
It took 50 years for the Nobel committee to acknowledge one of the key developments in biology...
22 August 2011 - by Antony Blackburn-Starza 
The United States Patent and Trademark Office (USPTO) has granted its first patent associated with induced pluripotent stem (iPS) cell technology to Professor Shinya Yamanaka of Kyoto University, Japan, for a technique used to reprogram fully differentiated somatic mouse cells into an embryonic-like state...
17 January 2011 - by Rose Palmer 
This is an extraordinary book about a woman who died on 4 October 1951, but whose legacy will continue exponentially. Henrietta Lacks was a poor black tobacco farmer who died, aged only 31, in the 'coloured ward' of John Hopkins Hospital in Baltimore....
5 January 2009 - by Adam Fletcher 
As 2008 drew to a close, Science magazine announced its annual top ten breakthroughs of the year, after considering novel research that 'paves the way for future discoveries'. Work in the field of cellular reprogramming was awarded pole position, ahead of a real-time video of a developing...
8 December 2008 - by Ben Jones 
The International Society for Stem Cell Research (ISSCR) has this week warned patients against unproven stem cell treatments being offered by rogue clinicians. The calls were made to governments to tighten their regulatory regimes to crack down on those exploiting the vulnerable with claims of revolutionary stem...
29 September 2008 - by Ben Jones 
Researchers at Massachusetts General Hospital, Boston, US, have developed a new, safer method for creating induced pluripotent stem (iPS) cells - adult cells made to behave like stem cells by inserting four key genes. Previously these genes have been delivered into cells using retroviruses, which can potentially trigger...
14 January 2008 - by Katy Sinclair 
The Japanese scientist whose team was responsible for the breakthrough that enabled human skin cells to be reprogrammed to behave like stem cells, Shinya Yamanaka from Kyoto University, has estimated that stem cell treatments for some diseases could be as little as a decade away. Stem cells...
26 November 2007 - by Dr Jess Buxton 
Two groups of scientists have managed to 'reprogramme' skin cells, retuning them to an embryonic-like state in which they regain the potential to develop into any type of body cell. The studies, published in the journals Cell and Science, pave the way for new research aimed...
11 June 2007 - by Ailsa Stevens 
By Ailsa Taylor: Three independent research groups have reported successfully causing skin cells from adult mice to revert back to an embryonic stem cell-like state; a technique that could potentially help to resolve the ongoing ethical debate over stem cell research. Published in the journal Nature, this groundbreaking research could...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.